This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.
Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.
Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360–76.
Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269–77.
Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27:1738–44.
Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), Gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013;31:4325–32.
Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J. 2015;5:e310.
Drach J, Angerler J, Schuster J, Rothermundt C, Thalhammer R, Haas OA, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood. 1995;86:3915–21.
Zandecki M, Obein V, Bernardi F, Soenen V, Flactif M, Lai JL, et al. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol. 1995;90:693–6.
Zandecki M, Lai JL, Genevieve F, Bernardi F, Volle-Remy H, Blanchet O, et al. Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. Blood. 1997;90:3682–90.
Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417–24.
Brousseau M, Leleu X, Gerard J, Gastinne T, Godon A, Genevieve F, et al. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients. Clin Cancer Res. 2007;13:6026–31.
Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119:2100–5.
Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harousseau JL, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 1999;59:4546–50.
Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812–7.
Acknowledgements
This work was supported in part by grants from the National Cancer Institute (CA168762 and CA107476).
Author information
Authors and Affiliations
Contributions
AL and SP collected and analyzed the data, wrote the first draft, and approved the final version of the manuscript; SVR, AD, MAG, FKB, MQL, DD, ALF, SRH, MAH, WIG, YLH, PK, NL, RSG, YL, TVK, RW, JAL, SJR and SRZ performed patient management, revised the manuscript critically, and approved the final version of the manuscript; RPK and PTG performed the FISH testing, revised the manuscript critically, and approved the final version of the manuscript; RAK performed patients’ follow-up, revised the manuscript critically, and participated in final data analysis and approval of the final version of the manuscript; and SKK designed the study, analyzed the data, wrote the first draft, approved the final version of the manuscript, and performed patient management.
Corresponding author
Ethics declarations
Conflict of interest
AD: Celgene, Takeda, Pfizer, Prothena and Alnylam (research funding). MAG: Johnson and Johnson (honoraria). PK: Takeda, Amgen and Sanofi (research funding) and Celgene and Sanofi (consulting fees). YL: Janssen (research funding). SKK: Abbvie, Celgene, Janssen, Merck, Novartis, Roche, Sanofi, and Takeda (research funding) and Skyline Diagnostics (honoraria). The remaining authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Lakshman, A., Paul, S., Rajkumar, S.V. et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia 32, 1811–1815 (2018). https://doi.org/10.1038/s41375-018-0030-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0030-3
This article is cited by
-
Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma
Journal of Human Genetics (2023)
-
Smoldering multiple myeloma current treatment algorithms
Blood Cancer Journal (2022)
-
Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects
Current Hematologic Malignancy Reports (2020)
-
Natural history of multiple myeloma with de novo del(17p)
Blood Cancer Journal (2019)
-
Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance
Leukemia (2018)